Effects of a curcumin-based supplementation in asymptomatic subjects with low bone density: a preliminary 24-week supplement study

Osteopenia is a chronic bone condition characterized by decreased calcification, density, or bone mass that, if untreated, can lead to osteoporosis and bone fractures. Although its increasing prevalence, nowadays osteopenia is not adequately prevented and managed. In this study, we evaluated the efficacy, in term of changes in bone density, and safety of an oral formulation based on turmeric phytosome (Meriva\uae), in subjects suffering from low bone density

A natural pharma standard supplement formulation to control treatment-related toxicity and oxidative stress in genitourinary cancer: a preliminary study

Oncological treatments are associated with toxicities that may decrease compliance to treatment in most genitourinary cancer patients. Supplementation with pharmaceutical-standardized supplement may be a supplementary method to control the side effects after chemo- and radiotherapy and the increased oxidative stress associated to treatments. This registry study evaluated a natural combination of supplements containing curcumin, cordyceps, and astaxanthin (Oncotris\u2122) used as supplementary management in genitourinary cancer patients who had undergone oncological therapy

Highly standardized cranberry extract supplementation (Anthocran\uae) as prophylaxis in young healthy subjects with recurrent urinary tract infections

Several studies have investigated the role of cranberry extract in the prevention of recurrent urinary tract infections (UTIs), on different selected subpopulations at increased risk of UTI. In this registry, we tested the prophylactic effects of an oral supplementation containing a highly standardized cranberry extract (Anthocran\uae) in young subjects with a previous history of recurrent UTIs, over a 2-months follow-up

A novel lecithin based delivery form of Boswellic acids (Casperome\uae) for the management of osteo-muscular pain: a registry study in young rugby players

Several experimental studies and clinical trials support the potential of Boswellia serrata extracts (BSE) for the treatment of various inflammatory diseases. The aim of this registry study was to assess the safety and the efficacy of a novel lecithin-based delivery form of Boswellia serrata extract (Casperome\uae) in the supportive management of osteo-muscular pain

Product-evaluation registry of Meriva\uae, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis

A proprietary complex of curcumin with soy phosphatidylcholine (Meriva\uae, Indena SpA) was evaluated in a registry study to define its efficacy in 50 patients with osteoarthritis (OA) at dosages corresponding to 200 mg curcumin per diem

Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome\uae) controls symptoms of mild irritable bowel syndrome

Irritable Bowel Syndrome (IBS) is a chronic, gastrointestinal disorder in which abdominal pain or discomfort is associated with defecation or changes in bowel habits. Its multifactorial pathophysiology leads to a variety of available treatments, mainly aimed at controlling symptoms. The management of IBS patients could be optimized by individualized strategies, including non-pharmaceutical approaches. In this study, we evaluated the efficacy and safety of a novel delivery form of Boswellia serrata extracts (BSE) (Casperome\uae) in patients with IBS

Pycnogenol® in postpartum symptomatic hemorrhoids

The aim of this registry study was to evaluate the efficacy of Pycnogenol\uae (Horphag Research Ltd.), a standardized extract from the French maritime pine bark, to control signs/symptoms and prevent complications associated with hemorrhoids in the months after delivery in healthy women. METHODS: Women with hemorrhoids after their second pregnancy were included within the third month after pregnancy. Pycnogenol dosage was 150 mg/day for 6 months. Symptoms for 4th and 3rd degree hemorrhoids were evaluated. RESULTS: The registry groups were comparable. For 4th degree hemorrhoids, main symptoms were reduced after 6 months in all patients, but the group using Pycnogenol in addition to standard best management showed more improvement. In patients with 3rd degree hemorrhoids, symptoms were reduced in both management groups at 6 months; with Pycnogenol the reduction in symptoms scores was significantly better. At 6 months 18/24 subjects (75%) in the Pycnogenol group were symptom-free in comparison with 14/25 (56%) in controls. In the 4th degree hemorrhoid group, 7/10 patients (70%) in the Pycnogenol group were symptom-free at 6 months in comparison with 4/11 subjects (36%) in the best management group. No significant side effects were observed. CONCLUSION: Pycnogenol appears to positively affect hemorrhoid signs and symptoms in the months after pregnancy

Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin

BACKGROUND: In this pilot non-interference clinical study we evaluated possible interactions between Quercetin Phytosome\uae (Quercefit\u2122), an innovative delivery form of quercetin, and antiplatelet agents, anticoagulants, and anti-diabetic therapy in otherwise healthy subjects. METHODS: Interaction with antiplatelet therapy was assessed through the bleeding time (BT) test in 30 patients treated with acetylsalicylic acid, ticlopidine or clopidogrel before and after 10 days of supplementation with Quercetin Phytosome\uae. Interaction with anticoagulants was evaluated by measuring the International Normalized Ratio (INR) in 20 patients using warfarin or dabigatran before and after 20 days of supplementation with Quercetin Phytosome\uae. Lastly, glycaemia and glycated hemoglobin were measured in 12 diabetic patients treated with metformin and restricted diet before and after 20 days of supplementation with Quercetin Phytosome\uae. RESULTS: After 10 days of supplementation no significant difference was observed in mean BT in patients treated with acetylsalicylic acid, ticlopidine or clopidogrel at standard dosages. Similarly, after 20 days of supplementation, the INRlevel among patients assuming warfarin or dabigatran was not statistically different from baseline. Lastly, no statistically significant difference in mean levels of glycaemia and glycated hemoglobin was reported before and after 20 days of complementary administration of Quercetin Phytosome\uae in diabetic patients treated with metformin and restricted diet. CONCLUSIONS: Quercetin Phytosome\uae does not alter the antiplatelet activity of the most common antiplatelet agents, has no impact on the INR values in stable patients treated with warfarin or dabigatran, and does not influence the metabolic control of diabetic patient treated with metformin

Linfavenix: miglioramento dei segni e sintomi dell'insufficienza venosa cronica e della microangiopatia. Uno studio prospettico sul modello acuto

Le samedi 9 septembre 2017, Arte a diffusé un documentaire court (25 min) consacré à l’histoire de l’"affaire de Roswell": une soucoupe volante se serait écrasée dans le Nouveau-Mexique en 1947 et aurait suscité croyances et théories du complot depuis cette époque. C'est du moins la version des faits que le documentaire ne va cesser de marteler pendant 25 minutes. Malheureusement cette version et le documentaire qui en résulte soulèvent plusieurs problèmes sérieux comme nous allons le voir. ..

Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study

This study evaluated the clinical efficacy of Venoruton (O-(beta-hydroxyethyl)-rutosides) (HR) (Novartis Consumer Healthcare) in subjects with severe chronic venous insufficiency (CVI)